Metastatic Bone Disease in the Era of Bone-Targeted Therapy: Clinical Impact
- 29 January 2013
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 99 (1) , 1-9
Abstract
Advances in the diagnosis and treatment of tumors by surgery, chemotherapy, biotherapy, radiotherapy and other modalities have increased the survival of cancer patients over the last 20 years. As a consequence, bone now represents the third most common site of metastatic involvement after the lung and liver. Approximately 20–25% of patients with neoplastic disease develop clinically evident bone metastases (BMs) during the natural course of their illness, with a further 50% of such lesions being identified during autopsy. BMs are the major cause of morbidity in cancer patients because of their epidemiological and clinical impact. Pain is the most frequent symptom in about 75% of patients but other serious complications can also occur, such as pathological fractures, spinal cord compression, hypercalcemia and bone marrow suppression. These complications worsen the patient's general condition and reduce patients’ mobility, facilitating the development of lung infections, skin ulcers, deep vein thrombosis, etc., and ultimately reducing prognosis and quality of life. The frequency of serious complications depends on the site and type of lesions and the treatment administered. Over the last 10 years, the introduction of bisphosphonates for the treatment of patients with BMs has led to a marked decrease in the frequency of complications, thus improving quality of life and clinical outcome. Furthermore, progress in understanding the pathophysiology of bone metastases has resulted in the development of new bone-targeted molecules such as denosumab. We therefore felt it would be useful to report on the epidemiological, clinical and economic impact of bone disease in a cancer setting.Keywords
This publication has 87 references indexed in Scilit:
- The combined use of surgery and radiotherapy to treat patients with epidural cord compression due to metastatic disease: a cost-utility analysisNeuro-Oncology, 2012
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United KingdomThe European Journal of Health Economics, 2010
- The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBritish Journal of Cancer, 2010
- Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudesAnnals of Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Metastatic bone disease: the requirement for improvement in a multidisciplinary approachInternational Orthopaedics, 2008
- CT Diagnosis of Rib Fractures and the Prediction of Acute Respiratory FailureJournal of Trauma: Injury, Infection & Critical Care, 2008
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- Osteoclast differentiation and activationNature, 2003